

Market Data

NDT Pharmaceuticals, Inc.
OTC: NDTP

Fiscal Year	Dec. 31
Price	\$1.06
52-week Range	\$0.03-\$1.20
Market Cap	\$169.6M
Shares Out.	160.0M
Float	16.9M
Avg. Vol (30-day)	10,056

Price & share data as of September 19, 2025

goodsaltlife.com



Company Overview

NDT Pharmaceuticals is a publicly traded health and wellness company redefining biosafety through its wholly owned subsidiary, Good Salt Life. Headquartered in Athens, Georgia, Good Salt Life is a vertically integrated innovator in infection control, combining cutting-edge chemical delivery technology, EPA-approved antimicrobial solutions, and data-driven disinfection protocols to create end-to-end biosafety ecosystems. With operations spanning 11 countries and 8 industries, the company's solutions are deployed across food production, animal health, healthcare, hospitality, transportation, and professional sports. Good Salt Life's multi-brand platform, serving consumer, commercial, and institutional markets, delivers scalable, eco-friendly solutions trusted by global leaders including Merck Animal Health, United Airlines, Carnival Cruise Line, Marriott, and the NFL.

Investment Highlights

Transforming biosafety with an integrated platform

- Vertically integrated model unites cutting-edge chemical delivery technology, EPA-approved antimicrobial solutions, and proprietary data-driven protocols
- One of the only players to own both the hardware and the chemistry, creating defensible IP and superior performance

Trusted by global leaders across industries

- Customers include Merck Animal Health, United Airlines, Carnival Cruise Line, Marriott, and the NFL
 - Strategic partnership with Merck Animal Health expands distribution through Merck's global networks and accelerates adoption in poultry, swine, aquaculture and companion animal markets with joint R&D initiatives
- Deployments active in 11 countries and 8 industries, spanning food production, animal health, healthcare, hospitality, transportation, and professional sport

Massive addressable market with high-growth opportunities

- \$148B+ total addressable market across animal health, food safety, consumer pet care, commercial biosafety, and more
- Forecasts project consumer pet hygiene market alone reaching \$65B in the U.S. by 2025

Expansive brand ecosystem and dual-channel growth strategy

- Multi-brand platform spans consumer pet care, home care, cosmetics, antimicrobial chemistry, and professional biosafety equipment
- Positioned for scale across both B2B and B2C markets, with 2026 as a key inflection point with national rollout and recurring revenue expansion

Strong revenue trajectory

- Revenue projected to scale from \$2.4M in 2025 to \$500M by 2030 through Merck distribution, direct-to-consumer channels, and international expansion

Trusted by Industry Leaders



Value Proposition

NDT Pharmaceuticals offers investors a compelling entry point into the rapidly expanding global biosafety and infection control market through its wholly owned subsidiary, Good Salt Life. As one of the only fully integrated platforms combining cutting-edge chemical delivery technology, EPA-approved antimicrobial solutions, and proprietary data-driven protocols, the company is uniquely positioned to address escalating demands for sustainable, effective pathogen control across food production, healthcare, hospitality, transportation, and consumer markets.

With a customer base that includes industry leaders such as Merck Animal Health, United Airlines, Carnival Cruise Line, Marriott, and the NFL, Good Salt Life has already demonstrated strong market validation. Its strategic partnership with Merck Animal Health accelerates distribution into global livestock and companion animal markets, while also driving joint innovation in consumer health and wellness products.

The company's scalable, multi-brand ecosystem provides exposure to both B2B and B2C growth, spanning professional biosafety, antimicrobial chemistry, and consumer health categories such as pet care and home care. With a \$148B+ total addressable market and clear tailwinds from heightened biosafety awareness and eco-conscious consumer demand, NDTP is positioned to capture significant market share.

Financially, Good Salt Life is projecting rapid growth from \$2.4M in 2025 to \$500M in revenue by 2030, driven by Merck-enabled global expansion, direct-to-consumer scale-up, and recurring revenue streams. Supported by a defensible IP portfolio, NDT Pharmaceuticals represents a high-growth, category-defining opportunity in health, safety, and wellness.

Brand Ecosystem

